| LDOS |
Report |
Non-GAAP EPS |
BEAT |
pred ~$3.05 vs. cons $2.90 |
MEDIUM |
| LDOS |
Report |
Revenue |
BEAT |
pred ~$4.48B vs. cons $4.43B |
MEDIUM |
| LDOS |
Report |
Adj. EBITDA margin |
IN-LINE |
pred ~13.6% vs. cons ~13.5% |
LOW |
| LDOS |
Guide |
FY26 non-GAAP EPS guide |
UNCHANGED |
guide ~$12.10-12.50 (midpoint $12.30) vs. cons $12.30 (FY26) |
MEDIUM |
| LDOS |
Guide |
FY26 revenue guide |
UNCHANGED |
guide ~$18.0-18.4B vs. cons ~$18.2B (FY26) |
MEDIUM |
| LDOS |
Guide |
Health/DHMSM (MHS GENESIS) commentary — revenue at risk & extension terms |
UNKNOWN |
guide TBD lead-integrator transition vs. cons assumes ~$0.5-1B Health run-rate risk (2H26/FY27) |
LOW |
| LDOS |
Guide |
Book-to-bill |
BETTER |
guide ~1.0x vs. cons ~0.9x (Q2, TTM ~1.1x) |
LOW |
| LDOS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
LOW |
| LDOS |
Return |
5-day cumulative residual |
+5.0% (FOLLOW-THROUGH) |
Sentiment is bombed-out (stock cut ~50% peak-to-trough) but has already bounced ~19% off the late-June $100 low into the print on a pre-telegraphed 'trough' quarter. A modest EPS/revenue beat plus a maintained FY guide and any constructive DHMSM extension/VBA reassurance validates the 'bad news is priced' thesis; at ~9-10x forward with a fresh 20M-share buyback authorization providing a bid, relief follows through. Risk skew: if DHMSM lead-integrator loss is confirmed or Health reset deepens, out-period math (2H hockey-stick doubts) pulls estimates down and flips this to a fade — hence low confidence. |
LOW |